title: [Metoprolol, a new effective antimigraine agent].
abstract: The effectiveness of metoprolol as a prophylactic treatment of migraine was investigated in double-blind comparative trials involving more than 500 patients. In two trials using a slow-release preparation and a dose of 200 mg per day, metoprolol proved significantly better than a placebo and as effective as propranolol 160 mg/day or flunarizine 10 mg/day. At the dose of 100 mg per day metoprolol was significantly more effective than clonidine and clomipramine and not different from a placebo, propranolol 80 mg/day or pizotifen 1.5 mg/day. It is concluded that metoprolol is useful as prophylactic treatment of migraine and ranks among the main drugs used for the same purpose, such as propranolol and pizotifen.
authors.affiliation: Laboratoires Astra France, Tour Avenir Quest, Nanterre.
authors.forename: C
authors.initials: C
authors.lastname: Raveau-Landon
authors.forename: M G
authors.initials: MG
authors.lastname: Bousser
mesh_terms: D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004361:Drug Tolerance; D006801:Humans; D008790:Metoprolol / Q000009:adverse effects / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000188:drug therapy*; D010919:Placebos
chemical_list: D010919:Placebos; D008790:Metoprolol
vernacular_title: Le métoprolol, nouvel antimigraineux de fond.